In the last trading session, 1.08 million shares of the Heron Therapeutics Inc (NASDAQ:HRTX) were traded, and its beta was 1.64. Most recently the company’s share price was $1.66, and it changed around -$0.08 or -4.60% from the last close, which brings the market valuation of the company to $252.48M. HRTX currently trades at a discount to its 52-week high of $3.93, offering almost -136.75% off that amount. The share price’s 52-week low was $1.04, which indicates that the current value has risen by an impressive 37.35% since then. We note from Heron Therapeutics Inc’s average daily trading volume that its 10-day average is 1.29 million shares, with the 3-month average coming to 3.20 million.
Heron Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 3 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended HRTX as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Heron Therapeutics Inc is expected to report earnings per share of -0.03 for the current quarter.
Heron Therapeutics Inc (NASDAQ:HRTX) trade information
Instantly HRTX has showed a red trend with a performance of -4.60% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.9099 on recent trading dayincreased the stock’s daily price by 13.08%. The company’s shares are currently up 8.50% year-to-date, but still down -1.78% over the last five days. On the other hand, Heron Therapeutics Inc (NASDAQ:HRTX) is 3.75% up in the 30-day period. We can see from the shorts that 31.06 million shares have been sold at a short interest cover period of 18.24 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 76.29% from its current value. Analyst projections state that HRTX is forecast to be at a low of $5 and a high of $9.
Heron Therapeutics Inc (HRTX) estimates and forecasts
The year-over-year growth rate is expected to be 10.88%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 37.37M in revenue for the current quarter. 1 analysts expect Heron Therapeutics Inc to make 34.25M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 34.23M and 34.67M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 9.15%. Forecasts for the next quarter put sales growth at -1.21%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 20.01%.
HRTX Dividends
Heron Therapeutics Inc’s next quarterly earnings report is expected to be released in March.
Heron Therapeutics Inc (NASDAQ:HRTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.86% of Heron Therapeutics Inc shares, and 81.15% of them are in the hands of institutional investors. The stock currently has a share float of 81.86%. Heron Therapeutics Inc stock is held by 206.0 institutions, with RUBRIC CAPITAL MANAGEMENT LP being the largest institutional investor. By 2024-06-30, it held 17.6678% of the shares, which is about 26.71 million shares worth $93.5 million.
VANGUARD GROUP INC, with 5.6984% or 8.62 million shares worth $30.16 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF were the top two Mutual Funds as of Sep 30, 2024 . The former held 4.68 shares worth $7.78 million, making up 3.08% of all outstanding shares. On the other hand, iShares Russell 2000 ETF held roughly 3.29 shares worth around $5.47 million, which represents about 2.17% of the total shares outstanding.
